Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C16:0-ceramide

Biochemical Pharmacology

Volumn 80, Issue 11, 2010, Pages 1632-1640

  Schiffmann, Susanne ^a   Ziebell, Simone ^a   Sandner, Jessica ^a   Birod, Kerstin ^a   Deckmann, Klaus ^a   Hartmann, Daniela ^a   Rode, Sina ^a   Schmidt, Helmut ^a   Angioni, Carlo ^a   Geisslinger, Gerd ^a   Grösch, Sabine ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

(Dihydro)ceramide synthase; C16:0 ceramide; Cancer; Celecoxib; Cyclooxygenase 2; SiRNA

Indexed keywords

CELECOXIB; CERAMIDE; CERAMIDE SYNTHASE 6; DESIPRAMINE; FUMONISIN B1; SMALL INTERFERING RNA; SYNTHETASE; THERMOZYMOCIDIN; UNCLASSIFIED DRUG; CERS6 PROTEIN, HUMAN; MEMBRANE PROTEIN; N-PALMITOYLSPHINGOSINE; PYRAZOLE DERIVATIVE; SPHINGOSINE ACYLTRANSFERASE; SULFONAMIDE;

ARTICLE; CELL STRAIN HCT116; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECTS; HCT116 CELL LINE; METABOLISM; MOUSE; NUDE MOUSE; PHYSIOLOGY; TISSUE DISTRIBUTION; TOXICITY;

ANIMALS; CELL PROLIFERATION; CERAMIDES; ENZYME ACTIVATION; HCT116 CELLS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; PYRAZOLES; SPHINGOSINE N-ACYLTRANSFERASE; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 77957924527     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.08.012     Document Type: Article

References (35)

1. Ogretmen B., Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004, 4(8):604-616.
2. Pewzner-Jung Y., Ben-Dor S., Futerman A.H. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J Biol Chem 2006, 281(35):25001-25005.
3. Rabionet M., van der Spoel A.C., Chuang C.C., von Tumpling-Radosta B., Litjens M., Bouwmeester D., et al. Male germ cells require polyenoic sphingolipids with complex glycosylation for completion of meiosis: a link to ceramide synthase-3. J Biol Chem 2008, 283(19):13357-13369.
4. Mizutani Y., Kihara A., Igarashi Y Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J 2005, 390(Pt 1):263-271.
5. Riebeling C., Allegood J.C., Wang E., Merrill A.H., Futerman AH Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J Biol Chem 2003, 278(44):43452-43459.
6. Laviad E.L., Albee L., Pankova-Kholmyansky I., Epstein S., Park H., Merrill A.H., et al. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 2008, 283(9):5677-5684.
7. Min J., Mesika A., Sivaguru M., Van Veldhoven P.P., Alexander H., Futerman A.H., et al. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res 2007, 5(8):801-812.
8. Ruvolo P.P. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003, 47(5):383-392.
9. Perry D.K., Carton J., Shah A.K., Meredith F., Uhlinger D.J., Hannun Y.A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J Biol Chem 2000, 275(12):9078-9084.
10. Charles A.G., Han T.Y., Liu Y.Y., Hansen N., Giuliano A.E., Cabot M.C. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 2001, 47(5):444-450.
11. Modrak D.E., Gold D.V., Goldenberg D.M. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006, 5(2):200-208.
12. Guenther G.G., Peralta E.R., Rosales K.R., Wong S.Y., Siskind L.J., Edinger A.L. Ceramide starves cells to death by downregulating nutrient transporter proteins. Proc Natl Acad Sci USA 2008, 105(45):17402-17407.
13. Selzner M., Bielawska A., Morse M.A., Rudiger H.A., Sindram D., Hannun Y.A., et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001, 61(3):1233-1240.
14. Koki A.T., Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002, 9(2 Suppl.):28-35.
15. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342(26):1946-1952.
16. Grosch S., Maier T.J., Schiffmann S., Geisslinger G Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006, 98(11):736-747.
17. Maier T.J., Tausch L., Hoernig M., Coste O., Schmidt R., Angioni C., et al. Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol 2008, 76(7):862-872.
18. Schiffmann S., Sandner J., Schmidt R., Birod K., Wobst I., Schmidt H., et al. The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res 2009, 50(1):32-40.
19. Brautigam L., Vetter G., Tegeder I., Heinkele G., Geisslinger G. Determination of celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2001, 761(2):203-212.
20. Schiffmann S., Sandner J., Birod K., Wobst I., Angioni C., Ruckhaberle E., et al. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 2009, 30(5):745-752.
21. Schiffmann S., Maier T.J., Wobst I., Janssen A., Corban-Wilhelm H., Angioni C., et al. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008, 76(2):179-187.
22. Elojeimy S., Holman D.H., Liu X., El-Zawahry A., Villani M., Cheng J.C., et al. New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 2006, 580(19):4751-4756.
23. Kudo N., Kumagai K., Tomishige N., Yamaji T., Wakatsuki S., Nishijima M., et al. Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide. Proc Natl Acad Sci USA 2008, 105(2):488-493.
24. Mukhopadhyay A., Saddoughi S.A., Song P., Sultan I., Ponnusamy S., Senkal C.E., et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 2008.
25. Ramer R., Weinzierl U., Schwind B., Brune K., Hinz B. Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol 2003, 64(5):1189-1198.
26. White-Gilbertson S., Mullen T., Senkal C., Lu P., Ogretmen B., Obeid L., et al. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 2009, 28(8):1132-1141.
27. Panjarian S., Kozhaya L., Arayssi S., Yehia M., Bielawski J., Bielawska A., et al. De novo N-palmitoylsphingosine synthesis is the major biochemical mechanism of ceramide accumulation following p53 up-regulation. Prostaglandins Other Lipid Mediat 2008, 86(1-4):41-48.
28. Liu X., Elojeimy S., Turner L.S., Mahdy A.E., Zeidan Y.H., Bielawska A., et al. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci 2008, 13:2293-2298.
29. Futerman A.H., Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol 2005, 15(6):312-318.
30. Bionda C., Portoukalian J., Schmitt D., Rodriguez-Lafrasse C., Ardail D. Subcellular compartmentalization of ceramide metabolism: MAM (mitochondria-associated membrane) and/or mitochondria?. Biochem J 2004, 382(Pt 2):527-533.
31. Yu J., Novgorodov S.A., Chudakova D., Zhu H., Bielawska A., Bielawski J., et al. JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction. J Biol Chem 2007, 282(35):25940-25949.
32. Maier T.J., Schiffmann S., Wobst I., Birod K., Angioni C., Hoffmann M., et al. Cellular membranes function as a storage compartment for celecoxib. J Mol Med 2009.
33. Koyanagi S., Kuga M., Soeda S., Hosoda Y., Yokomatsu T., Takechi H., et al. Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide synthase. Int J Cancer 2003, 105(1):1-6.
34. Group A.R., Lyketsos C.G., Breitner J.C., Green R.C., Martin B.K., Meinert C., et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68(21):1800-1808.
35. Katsel P., Li C., Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?. Neurochem Res 2007, 32(4-5):845-856.